Shire Is Agnostic On Baxalta's Biosimilars Pipeline As Integration Begins
This article was originally published in The Pink Sheet Daily
Executive Summary
In an interview, CEO Ornskov notes that prioritization of combined company's assets is only just beginning with closing of the $32bn merger.